News
Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...
Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 10 Stocks Crash Hard Alongside Wall Street. Apogee Therapeutics fell by ...
Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...
Investor's Business Daily on MSN3d
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...
President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...
View the latest Apogee Therapeutics Inc. (APGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...
Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...
Cogent Biosciences reported results from a Phase 3 study of bezuclastinib in indolent systemic mastocytosis, the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback